One-Pot Fabrication of Hollow Porphyrinic MOF Nanoparticles with Ultrahigh Drug Loading toward Controlled Delivery and Synergistic Cancer Therapy

2021 ◽  
Vol 13 (3) ◽  
pp. 3679-3693
Author(s):  
Xin Sun ◽  
Guihua He ◽  
Chuxiao Xiong ◽  
Chenyuan Wang ◽  
Xiang Lian ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Drug Loading ◽  
Controlled Delivery ◽  
One Pot

Hyaluronan based Multifunctional Nano-carriers for Combination Cancer Therapy

2020 ◽  
Vol 20 ◽  
Author(s):  
Menghan Gao ◽  
Hong Deng ◽  
Weiqi Zhang
Keyword(s):  
Cancer Therapy ◽  
Combination Therapy ◽  
Cancer Cells ◽  
Drug Loading ◽  
Tumor Therapy ◽  
Drug Carriers ◽  
Functional Sites ◽  
Therapeutic Modalities ◽  
Combination Cancer Therapy ◽  
Targeting Strategy

: Hyaluronan (HA) is a natural linear polysaccharide that has excellent hydrophilicity, biocompatibility, biodegradability, and low immunogenicity, making it one of the most attractive biopolymers used for biomedical researches and applications. Due to the multiple functional sites on HA and its intrinsic affinity for CD44, a receptor highly expressed on various cancer cells, HA has been widely engineered to construct different drug-loading nanoparticles (NPs) for CD44- targeted anti-tumor therapy. When a cocktail of drugs is co-loaded in HA NP, a multifunctional nano-carriers could be obtained, which features as a highly effective and self-targeting strategy to combat the cancers with CD44 overexpression. The HA-based multidrug nano-carriers can be a combination of different drugs, various therapeutic modalities, or the integration of therapy and diagnostics (theranostics). Up to now, there are many types of HA-based multidrug nano-carriers constructed by different formulation strategies including drug co-conjugates, micelles, nano-gels and hybrid NP of HA and so on. This multidrug nano-carrier takes the full advantages of HA as NP matrix, drug carriers and targeting ligand, representing a simplified and biocompatible platform to realize the targeted and synergistic combination therapy against the cancers. In this review, recent progresses about HA-based multidrug nano-carriers for combination cancer therapy are summarized and its potential challenges for translational applications have been discussed.

Preclinical investigations revealed possibilities for Salmonella tumor treatment. Bacteria can also be coupled to nanomaterials enabling drug-loading, photocatalytic and/or magnetic properties, using the bacteria's net negative charge

2021 ◽  
Author(s):  
Moataz Dowaidar
Keyword(s):  
Clinical Trials ◽  
Cancer Therapy ◽  
Cancer Treatment ◽  
Negative Charge ◽  
Human Cancer ◽  
Drug Loading ◽  
Tumor Therapy ◽  
Preclinical Research ◽  
Immunodeficient Mice ◽  
Virulence Attenuation

Except in human clinical trials, preclinical tests showed the potential of Salmonella bacteria for tumor therapy. There are still various challenges to tackle before salmonella bacteria may be employed to treat human cancer. Due to its pathogenic nature, attenuation is essential to minimize the host's harmful effects of bacterial infection. Loss of anticancer efficacy from bacterial virulence attenuation can be compensated by giving therapeutic payloads to microorganisms. Bacteria can also be linked to micro-or nanomaterials with diverse properties, such as drug-loaded, photocatalytic and/or magnetic-sensing nanoparticles, using the net negative charge of the bacteria. Combining bacteria-mediated cancer treatment with other medicines that have been clinically shown to be helpful but have limits may provide surprising therapeutic results. Recently, this strategy has received attention and is underway. The use of live germs for cancer treatment has not yet been approved for human clinical trials. The non-invasive oral form of administration benefits from safety, making it more suitable for clinical cancer patients.Infection of live germs through systemic means, on the other hand, involves toxicity risk. Although Salmonella bacteria can be genetically manipulated with high tumor targeting, harm to normal tissues can not be excluded when medications with nonspecific toxicity are administered. It is preferred if the action of selected drugs may be restricted to the tumor site rather than healthy tissues, thereby boosting cancer therapy safety. In recent years, many regulatory mechanisms have been developed to manage pharmaceutical distribution through live bacterial vectors. Engineered salmonella can accumulate 1000 times greater than normal tissue density in the tumor. The QS-regulated mechanism, which initiates gene expression when bacterial density exceeds a particular threshold level, also promises Salmonella bacteria for targeted medication delivery. Nanovesicle structures of Salmonella bacteria can also be used as biocompatible nanocarriers to deliver functional medicinal chemicals in cancer therapy. Surface-modified nanovesicles preferably attach to tumor cells and are swallowed by receptor-mediated endocytosis before being destroyed to release packed drugs. The xenograft methodology, which comprises the implantation of cultivated tumor cell lines into immunodeficient mice, has often been used in preclinical research revealing favorable results about the anticancer effects of genetically engineered salmonella.

A Low Dose of Hydrous Icaritin Nano-Formulation with Remarkable Efficacy and Tumor Targeting in Cancer Therapy

2021 ◽  
Vol 17 (10) ◽  
pp. 2003-2013
Author(s):  
Jingxin Fu ◽  
Yian Wang ◽  
Haowen Li ◽  
Likang Lu ◽  
Hui Ao ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Tumor Targeting ◽  
Low Dose ◽  
Drug Loading ◽  
Tumor Therapy ◽  
High Dose ◽  
Inhibition Rate ◽  
Tumor Inhibition ◽  
Nano Formulation ◽  
Tumor Inhibition Rate

Background: The use of chemotherapeutic drugs is restricted in the tumor-therapy because of the severely toxic and side effects among most important factors. The active herbal extracts are always used as a high dose while in the tumortherapy to achieve good anti-tumor effects. Hydrous icaritin has a high activity while there are few existing dosage forms as a result of low solubility in water and poor bioavailability. Results: The prepared hydrous icaritin nanorods (DP-HICT NRs) using mPEG2000-DSPE as a stabilizer, presented a narrow distribution of particle size with of 217 nm and a properly high drug-loading content of approximately 65.3±1.5%. A low dose of hydrous icaritin nano-formulation shows remarkable efficacy in cancer therapy (tumor inhibition rate: 61.36±10.80%) compared with the same dose of Paclitaxel injection (tumor inhibition rate: 66.80±4.43%), which approved as medicaments. Not only that, DP-HICT NRs can escape the clearance of the immune system and enhance targeting ability to the tumor site with only one excipient and such a low dose. Conclusions: This kind of nanoparticles contain a low dose of HICT used mPEG2000-DSPE as a stabilizer, while can achieve good tumor targeting as some active targeting agents and an anti-tumor effect as the PTX injection. There are broad prospects in drug safety, anti-tumor efficacy and even prognosis.

scholarly journals A radio-theranostic nanoparticle with high specific drug loading for cancer therapy and imaging

2015 ◽  
Vol 217 ◽  
pp. 170-182 ◽  
Author(s):  
Andrew B. Satterlee ◽  
Hong Yuan ◽  
Leaf Huang
Keyword(s):  
Cancer Therapy ◽  
Drug Loading ◽  
Specific Drug

scholarly journals Extracellular Vesicles: An Emerging Nanoplatform for Cancer Therapy

2021 ◽  
Vol 10 ◽  
Author(s):  
Yifan Ma ◽  
Shiyan Dong ◽  
Xuefeng Li ◽  
Betty Y. S. Kim ◽  
Zhaogang Yang ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Extracellular Vesicles ◽  
Drug Delivery Systems ◽  
Current Knowledge ◽  
Drug Loading ◽  
Cell Communication ◽  
Cancer Therapies ◽  
Therapeutic Function ◽  
Cancer Studies ◽  
Potential Use

Extracellular vesicles (EVs) are cell-derived membrane particles that represent an endogenous mechanism for cell-to-cell communication. Since discovering that EVs have multiple advantages over currently available delivery platforms, such as their ability to overcome natural barriers, intrinsic cell targeting properties, and circulation stability, the potential use of EVs as therapeutic nanoplatforms for cancer studies has attracted considerable interest. To fully elucidate EVs’ therapeutic function for treating cancer, all current knowledge about cellular uptake and trafficking of EVs will be initially reviewed. In order to further improve EVs as anticancer therapeutics, engineering strategies for cancer therapy have been widely explored in the last decade, along with other cancer therapies. However, therapeutic applications of EVs as drug delivery systems have been limited because of immunological concerns, lack of methods to scale EV production, and efficient drug loading. We will review and discuss recent progress and remaining challenges in developing EVs as a delivery nanoplatform for cancer therapy.

Recent advances in anti-angiogenic nanomedicines for cancer therapy

Nanoscale ◽  
2018 ◽  
Vol 10 (12) ◽  
pp. 5393-5423 ◽  
Author(s):  
Pravin Bhattarai ◽  
Sadaf Hameed ◽  
Zhifei Dai
Keyword(s):  
Cancer Therapy ◽  
Controlled Delivery ◽  
Therapeutic Success ◽  
Vessel Normalization ◽  
Recent Advances

The controlled delivery of nanomedicine-based antiangiogenic inhibitors or chemotherapeutics can revitalize therapeutic success by vessel normalization.

Preparation of a one-dimensional nanorod/metal organic framework Janus nanoplatform via side-specific growth for synergistic cancer therapy

2019 ◽  
Vol 7 (4) ◽  
pp. 1696-1704 ◽  
Author(s):  
Haipeng Zhang ◽  
Qin Zhang ◽  
Chunshui Liu ◽  
Bing Han
Keyword(s):  
Cancer Therapy ◽  
Specific Growth ◽  
Metal Organic Framework ◽  
Drug Loading ◽  
Ct Image ◽  
One Dimensional ◽  
Image Guided ◽  
Metal Organic ◽  
Organic Framework

A unique LA-AuNR/ZIF-8 Janus nanoparticle is firstly prepared by side-specific growth of ZIF-8 on one-dimensional AuNR for drug loading to realize the CT image-guided active targeted synergistic chemo-photothermal cancer therapy.

Co-delivery of dual chemo-drugs with precisely controlled, high drug loading polymeric micelles for synergistic anti-cancer therapy

2020 ◽  
Vol 8 (3) ◽  
pp. 949-959 ◽  
Author(s):  
Yuchen Wu ◽  
Shixian Lv ◽  
Yongjuan Li ◽  
Hua He ◽  
Yong Ji ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Polymeric Micelles ◽  
Drug Loading ◽  
High Drug ◽  
Delivery Strategy ◽  
Anti Cancer ◽  
High Drug Loading

The introduction of donor-receptor coordination between micelles and drug payloads provides a precise co-delivery strategy for two different chemo-drugs with high drug loading and ROS responsiveness.

scholarly journals Controlled delivery of a protein tyrosine phosphatase inhibitor, SHP099, using cyclodextrin-mediated host–guest interactions in polyelectrolyte multilayer films for cancer therapy

RSC Advances ◽  
2020 ◽  
Vol 10 (34) ◽  
pp. 20073-20082 ◽  
Author(s):  
Soobin Wang ◽  
Alessia Battigelli ◽  
Dahlia Alkekhia ◽  
Alexis Fairman ◽  
Valentin Antoci ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Anticancer Drug ◽  
Protein Tyrosine Phosphatase ◽  
Multilayer Film ◽  
Tyrosine Phosphatase ◽  
Multilayer Films ◽  
Controlled Delivery ◽  
Polyelectrolyte Multilayer ◽  
Supramolecular Complexation ◽  
Protein Tyrosine Phosphatase Inhibitor

Controlled delivery of a potent anticancer drug, SHP099, after supramolecular complexation into a versatile multilayer film.

Sign in / Sign up

Export Citation Format

Share Document